Dynamics of multiple myeloma tumor therapy with a recombinant measles virus (Q33652517)

28 July 2017

Dynamics of multiple myeloma tumor therapy with a recombinant measles virus (English)

1 reference

28 July 2017

1 reference

1

D Dingli

1 reference

28 July 2017

C Offord

2

1 reference

28 July 2017

R Myers

3

1 reference

28 July 2017

K-W Peng

4

1 reference

28 July 2017

T W Carr

5

1 reference

28 July 2017

K Josic

6

1 reference

28 July 2017

S J Russell

7

1 reference

28 July 2017

Z Bajzer

8

1 reference

28 July 2017

5 June 2009

1 reference

28 July 2017

1 reference

28 July 2017

16

1 reference

28 July 2017

12

1 reference

28 July 2017

873-882

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2009.40

28 July 2017

0 references

cites work

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Immunodeficiency and immunotherapy in multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Viruses as anticancer drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Interaction of measles virus vectors with Auger electron emitting radioisotopes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

RNA viruses as virotherapy agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Herpes oncolytic therapy of salivary gland carcinomas

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Mathematical modeling of cancer radiovirotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

A mathematical model of the impact of infused targeted cytotoxic agents on brain tumours: implications for detection, design and delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Modeling and analysis of a virus that replicates selectively in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Systemic therapy of myeloma xenografts by an attenuated measles virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Modeling of cancer virotherapy with recombinant measles viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Decelerating growth and human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

A new look at the statistical model identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Oncolytic measles virus targets high CD46 expression on multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2009.40

Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Intraperitoneal therapy of ovarian cancer using an engineered measles virus.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Viruses as antitumor weapons: defining conditions for tumor remission.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Gompertzian growth as a self-similar and allometric process.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821809

Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19498461

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Reengineering paramyxovirus tropism

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19498461

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rescue and propagation of fully retargeted oncolytic measles viruses

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19498461

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/CGT.2009.40

1 reference

28 July 2017

1 reference

28 July 2017

1 reference